Oct 28, 2024
Pfizer’s ABRYSVO became the first and only RSV vaccine approved for use in adults under 50, offering the most extensive RSV vaccine coverage for adults. The label expansion announced on 22 October 2024 includes younger adults considered at higher risk for RSV-related lower respiratory tract disease (LRTD). &nb...
Read More...
Oct 25, 2024
Exosome therapies represent an exciting frontier in the development of novel treatments for a wide range of diseases. The ability to harness the natural communication system of cells offers unparalleled potential for precise and effective treatments. While challenges remain, ongoing research and technological advan...
Read More...
Oct 24, 2024
iRhythm Technologies Received FDA 510(k) Clearance for Design Updates Previously Made to Its Zio® AT Device On October 21, 2024, iRhythm Technologies, Inc., a leading digital healthcare company specializing in solutions to detect, predict, and prevent disease, announced that the U.S. Food and Drug Administ...
Read More...
Oct 23, 2024
Plasma protein therapeutics are revolutionizing the landscape of modern medicine by harnessing the healing potential of the human body. Derived from donated blood plasma, these life-saving treatments are packed with antibodies, clotting factors, and other essential proteins that help manage a wide array of conditio...
Read More...
Oct 22, 2024
Gilead and Merck Reports Phase II Data Showing that Switching to a Once-Weekly Oral Combination of Islatravir and Lenacapavir Maintained Viral Suppression in Adults Through 48 Weeks Gilead Sciences, Inc. and Merck have shared new findings from a Phase II clinical trial assessing the experimental combination of i...
Read More...
Oct 21, 2024
Exosomes are tiny, powerful messengers that are revolutionizing the way we think about communication between cells. These nanosized vesicles carry crucial signals—proteins, lipids, and RNA—between cells, playing a pivotal role in everything from immune responses to tissue repair. What makes exosomes truly exciting ...
Read More...
Oct 18, 2024
In the ever-evolving world of liver disease, the shift from Nonalcoholic Steatohepatitis (NASH) to Metabolic Associated Steatotic Hepatitis (MASH) marks a revolutionary leap in our understanding and approach to treatment. This transition isn't merely a rebranding; it signifies a profound recognition of the intricat...
Read More...
Oct 17, 2024
FDA Approved Roche’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation On October 11, 2024, Roche announced that the United States Food and Drug Administration (FDA) approved Itovebi™ (inavolisib), in combination with palbociclib (Ibran...
Read More...
Oct 16, 2024
Pompe disease is a rare genetic disorder that presents a spectrum of severity, with varying rates of progression and ages of onset. Symptoms can appear anywhere from infancy to late adulthood, with earlier onset generally associated with more rapid progression and increased severity. At all ages, the disease is mar...
Read More...
Oct 15, 2024
Astellas & AviadoBio Sign Exclusive Deal for Gene Therapy AVB-101 in Frontotemporal Dementia AviadoBio Ltd. and Astellas Pharma Inc. have announced a strategic partnership under an exclusive option and license agreement for AVB-101, an investigational AAV-based gene therapy currently in Phase I/II developmen...
Read More...